Multiple Sclerosis, Chronic Progressive - 25 Studies Found

Completed : Safety Study of an Immunomodulating Microparticle to Treat Progressive Multiple Sclerosis
:
  • Secondary Progressive Multiple Sclerosis
  • Primary Progressive Multiple Sclerosis

: 2010-08-30
: Biological: MIS416 MIS416 intravenously every week
Completed : Sunphenon in Progressive Forms of Multiple Sclerosis
: Multiple Sclerosis
: 2008-11-28
:
  • Drug: Sunphenon EGCG 200-800mg
Recruiting : A LOW-COST VIRTUAL REALITY GAMING PLATFORM FOR NEUROREHABILITATION OF HEMIPARESIS
:
  • Primary Progressive Multiple Sclerosis
  • Hemiparesis

: 2017-03-23
: Behavioral: Gaming CI Therapy Intensive remote (via video game) therapy for upper extremity hemiparesis.
Recruiting : Dimethyl Fumarate Treatment of Primary Progressive Multiple Sclerosis
: Primary Progressive Multiple Sclerosis
: 2016-11-08
:
  • Drug: Dimethyl Fumarate Other

Recruiting : Hydroxychloroquine in Primary Progressive Multiple Sclerosis
: Multiple Sclerosis, Primary Progressive
: 2016-09-20
: Drug: Hydroxychloroquine Orally administered Hydroxychloroquine
Available : Expanded Access Program for Ocrelizumab in Participants With Primary Progressive Multiple Sclerosis
: Multiple Sclerosis
: 2016-06-16
: Drug: Ocrelizumab Participants will receive 600 mg ocrelizumab as two 300 mg infusions separated by 14 d
Recruiting : Study to Explore the Mechanism of Action of Ocrelizumab and B-Cell Biology in Participants With Relapsing Multiple Sclerosis (RMS) or Primary Progressive Multiple Sclerosis (PPMS)
:
  • Relapsing Multiple Sclerorsis
  • Multiple Sclerosis, Primary Progressive

: 2016-02-18
:
  • Drug: Ocrelizumab Ocrelizumab

Completed : Pharmacokinetics of DMF and the Effects of DMF on Exploratory Biomarkers
: Multiple Sclerosis
: 2016-01-14
: Drug: BG00012 (DMF) (Tecfidera®.) Subjects will take DMF 120 mg BID for the first 4 weeks of treatm
Active, not recruiting : A Phase 2 Clinical Study in Subjects With Primary Progressive Multiple Sclerosis to Assess the Efficacy, Safety and Tolerability of Two Oral Doses of Laquinimod Either of 0.6 mg/Day or 1.5mg/Day (Experimental Drug) as Compared to Placebo
: Primary Progressive Multiple Sclerosis
: 2014-10-31
:
  • Drug: Laquinimod Laquinimod 0.
Active, not recruiting : Efficacy, Safety and Tolerability of Andrographolides Versus Placebo in Patients With Progressive Forms of MS
:
  • Primary Progressive Multiple Sclerosis
  • Multiple Sclerosis, Secondary Progressive

: 2014-10-03
:
  • Drug: Andrographolides 140 mg

<<< Previous | Next >>>